Predominant emphasis will be placed on 2021 and expectations for the following year's development, when Demant hands in its yearly fiscal report Tuesday morning.
Following a couple of grim years starting with a hacker attack in September 2019, and following by the Covid-19 crisis last year, the ground has been laid for a more normalized 2021 for Demant, which is, however, still influenced by uncertainty caused by national lockdowns around the world.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.